In the other phase 2b trial, MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure ARTS-HF (NCT01807221), comparing different doses of finerenone to eplerenone, there were no statistically significant differences in the incidence of TEAE between the finerenone groups and the eplerenone group nor a significant difference in the incidence of hyperkalemia. This evidence concerns the gene NR3C2 and heart failure.